オプションチェーンは、Upstream Bioの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Upstream Bioの市場センチメントを評価します。.

Upstream Bio (NASDAQ:UPB) 株価情報, オプションチェーン

Upstream Bio

Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.

Upstream Bio Inc

Upbound Group Inc

UNITED PLANT BERHAD ORD by United Plantations Berhad

United Plantation Bhd

UPBOUND GROUP ORD

UpBots

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

News

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

Price Target

Analyst Ratings

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

NSSC

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

Emerson and its affiliates currently own 57.4% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated November 5, 2024.
The Board of Directors of AspenTech will follow an appropriate governance process and carefully review the proposal. No action is required by AspenTech shareholders at this time. &nbsp;

AZPN

Aspen Technology Confirms Receipt Of $240/Share Unsolicited Acquisition Proposal From Emerson; Asks Shareholders Not To Take Any Action Pending Review

DA Davidson analyst Brent Thielman maintains Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) with a Neutral and raises the price target from $41 to $47.

DA Davidson Maintains Neutral on Summit Materials, Raises Price Target to $47

Guidance

PAAS

Pan American Silver Reaffirms Its 2024 Operating Outlook For Annual Production, Cash Costs And AISC, And Capital Expenditures

Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 3100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $716.10 million which beat the analyst consensus estimate of $699.01 million by 2.44 percent. This is a 16.19 percent increase over sales of $616.30 million the same period last year.

Earnings

Earnings Beats

Pan American Silver Q3 2024 Adj EPS $0.32 Beats $0.21 Estimate, Sales $716.10M Beat $699.01M Estimate

DA Davidson analyst Kevin Fitzsimmons maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Buy and lowers the price target from $41 to $38.

DA Davidson Maintains Buy on Origin Bancorp, Lowers Price Target to $38

DA Davidson analyst Gil Luria maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Neutral and raises the price target from $28 to $47.

PLTR

DA Davidson Maintains Neutral on Palantir Technologies, Raises Price Target to $47

The 2024 U.S. presidential election between Vice President Kamala Harris and former President Donald Trump remains one of the closest in history, raising concerns over whether the U.S. Supreme Court may play a decisive role in <a href="https://www.benzinga.com/topic/2024-election">determining the outcome. </a>
As voters head to the polls, election-related legal battles already hint at the possibility of judicial involvement, The New York Times <a href="https://www.nytimes.com/2024/11/05/us/politics/election-supreme-court.html">reports</a>.
What Happened: Several election cases have reached the Supreme Court in recent weeks, including a decision to allow Virginia's removal of over 1,600 voters from its rolls and rulings affecting candidates and voters in battleground states. 
The court decided against removing Robert F. Kennedy Jr. from ballots in key states and authorized provisional ballots in Pennsylvania, after some mail-in ballots were deemed invalid. These cases showcase the judiciary's cautious approach to electoral involvement, although the court's conservative majority could still play a critical role if a close race sparks significant litigation, according to The New York Times.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41759661/us-election-jitters-meet-interest-rate-cut-assurance-why-feds-powell-may-offer-tr">US Election Jitters Meet Interest-Rate Cut Assurance: Why Fed&#8217;s Powell May Offer Traders A Safe Harbor This Week</a>
The Supreme Court's involvement would hinge on an exceptionally narrow vote margin in a critical state, experts say. Prof. Richard Pildes of New York University told The New York Times that a paper-thin margin in a state like Pennsylvania, with its 19 electoral votes, could increase the likelihood of a court ruling influencing the presidential outcome.
Still, experts are cautious, noting that the Supreme Court generally aims to avoid direct involvement in elections.
Beyond the presidential race, the stakes extend to congressional control. Democrats seek to retain the Senate and flip the House, while Republicans push for gains in both chambers. The outcomes in Senate races, including those in Montana and Ohio, could shift control, particularly if Democratic seats in battleground states like Michigan and <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">Pennsylvania face Republican challenges.</a> 
Why It Matters: A Supreme Court decision might not only impact the presidency but also influence control over Congress, setting a precedent for election litigation. In a scenario reminiscent of the Bush v. Gore case in 2000, if margins are close enough, legal challenges could escalate to the highest court. 
The potential for either party to control both chambers or split Congress suggests significant implications for the future of U.S. legislation and governance, The New York Times notes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41756372/robinhoods-election-contracts-hit-200-million-trades-on-election-day">Robinhood&#8217;s Election Contracts Hit 200 Million Trades On Election Day</a></li>
</ul>
This article was generated using artificial intelligence and was reviewed by Benzinga editors.
Photo: Shutterstock

Government

Politics

Legal

Supreme Court Could Step In If 2024 Election Remains Deadlocked

SMCI

Super Micro Computer CEO Says Don't Expect Negative Allocation From NVIDIA

Super Micro Computer CEO Says He Has An 'Open Mind' About Separating CEO And Chairman Roles

Gerdau Reports Q3 Adjusted EBITDA Of R$3.0B, Up 14.9% Q/Q

Murchinson Ltd. holds approximately 7.1% of the outstanding shares of Nano Dimension.

NNDM

Murchinson Urges Nano Dimension Shareholders To Vote For Its Independent Nominees; Sends Letter Highlighting Company's Questionable Acquisitions

TD Bank Expects Catastrophe Claims Of $388M After Reinsurance And Before Tax To Be Reflected In Wealth Management & Insurance Segment's Q4 Results

Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) reported third-quarter financial results after the market close Tuesday, the same day Donald Trump is facing off against Kamala Harris in the <a href="https://www.benzinga.com/news/24/11/41758791/whats-going-on-with-trump-media-technology-group-stock-tuesday">2024 presidential election.</a>
What Happened: Trump Media &amp; Technology Group announced third-quarter net sales of $1.01 million, down 6% year-over-year, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company <a href="https://s3.amazonaws.com/sec.irpass.cc/2660/0001140361-24-045260.pdf">said </a>all of its revenue came from advertising on the Truth Social platform in the quarter.
The company reported a loss of 10 cents per share compared to a loss of 30 cents per share in last year's third quarter.
Trump Media &amp; Technology Group, which was co-founded by the former president, highlighted the importance of Trump for the company's success.
"TMTG's success depends in part on the popularity of our brand and the reputation and popularity of President Donald J. Trump. The value of TMTG's brand may diminish if the popularity of President Donald J. Trump were to suffer," the company said.
Trump is able to post politically related posts on any social media site at any time, including outside of Truth Social, the filing said. 
The filing lists a date of Feb. 2, 2025 for when Trump may "terminate the Exclusivity Obligation" with 30 days prior written notice for his non-political posts to appear first on Truth Social.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110524">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: The quarterly filing said the company plans to roll out its streaming content in three phases.
<ul>
<li>Phase 1: Introduce Truth Social for streaming live TV to the Truth Social app for Android, iOS and Web</li>
<li>Phase 2: Release standalone Truth Social over-the-top streaming apps for phones, tablets and other devices</li>
<li>Phase 3: Release Truth Social streaming apps for home TV</li>
</ul>
The company said it completed phase 1 in August, phase 2 in October and as of Oct. 23, phase 3 has seen the Truth+ streaming platform released on Apple TV, Android TV and Amazon Fire TV.
Future growth initiatives from the company include growing the initial Truth Social platform, increasing product offerings and pursuing strategic acquisitions and/or partnerships.
The company said it plans to expand the business operations globally.
Trump Media &amp; Technology Group ended the third quarter with $672 million in cash, cash equivalents and short-term investments.
DJT Price Action: Shares of Trump Media &amp; Technology Group saw increased volatility Tuesday ahead of the 2024 election with shares halted twice Tuesday.
Shares traded between $31.45 and $40.74 on Tuesday before closing down 1% to $33.94.
The stock is trading 2,.2% higher after hours at $4.69. 
Trump Media &amp; Technology Group stock is likely to experience increased volatility during the week as investors await the results of the 2024 election, with a potential Trump win viewed as a positive for the stock and a Trump loss viewed as a negative for the stock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41732623/bakery-that-often-predicts-election-outcomes-has-this-candidate-winning-in-trump-harris-battle-d" target="_blank" rel="noreferrer noopener">Bakery That Often Predicts Election Outcomes Has This Candidate Winning In Trump, Harris Battle: ‘Doughmacracy For All!'</a></li>
</ul>

Equities

Social Media

Markets

Movers

Trading Ideas

DJT Stock Volatile On Election Day: Donald Trump's Media Company Reports Q3 Earnings, Growth Initiatives

Jones Trading analyst Jason Weaver maintains Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) with a Buy and maintains $15 price target.

FBRT

Jones Trading Maintains Buy on Franklin BSP Realty Trust, Maintains $15 Price Target

Super Micro Computer CEO Says Its Servers Are Ready For Production When NVIDIA Chips Arrive

CVS Health, Apollo Global Management, And Novo Nordisk Reported Results

Polyrizon and Gelteq made their public debut on Tuesday in a quiet Halloween week for the IPO market. LATEST IPOS AND DIRECT LISTINGS: Polyrizon (P...

Opening Day: Polyrizon, Gelteq debut in quiet IPO week

William Blair initiated coverage of Upstream Bio (UPB) with an Outperform rating. Published first on TheFly – the ultimate source for real-time, ma...

Upstream Bio initiated with an Outperform at William Blair

Yasmeen Rahimi, an analyst from Piper Sandler, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Yasmeen Rahimi has given her Buy rating ...

Promising Market Impact: Yasmeen Rahimi's Buy Rating on Upstream Bio's Verekitug for Asthma and COPD

Tessa Romero, an analyst from J.P. Morgan, has initiated a new Buy rating on Upstream Bio, Inc. (UPB). Tessa Romero's rating is based on the promis...

Positive Buy Rating for Upstream Bio Driven by Verekitug's Potential in Severe Asthma and Expansion into CRSwNP and COPD Markets

Piper Sandler initiated coverage of Upstream Bio (UPB) with an Overweight rating and $75 price target The analyst believes Upstream's verekitug has...

Upstream Bio initiated with an Overweight at Piper Sandler

JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam's lead asset is verekitug, a recombinant h...

Upstream Bio initiated with an Overweight at JPMorgan

Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by TD Cowen analyst, Yaron Werber. Yaron Werber has given his Buy rating due to a...

Promising Prospects for Upstream Bio's Verekitug: A Potential Blockbuster in Inflammatory Disease Treatment

TD Cowen initiated coverage of Upstream Bio (UPB) with a Buy rating. The firm says the company's verekitug is a "differentiated fast follower" with...

Upstream Bio initiated with a Buy at TD Cowen

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Dollar Tree downgraded, eBay upgraded: Wall Street's top analyst calls

AAPL

ABNB

ALRM

ANET

CAMP

CBLL

CLIK

CNTY

CPRI

CTVA

CVNA

DLTR

DNUT

EBAY

FANG

FSLR

FSUN

FTNT

GELS

GILD

HMST

HUBB

IDYA

ILMN

MCHP

MELI

MSFT

NXPI

PARA

PARAA

PLRZ

QCOM

QRVO

RACE

RDDT

ROIC

SAVE

SKYQ

STFS

TTWO

VEEV

VRTX

Financing

IPOs

Press Releases

Upstream Bio Announces Pricing of Upsized Initial Public Offering

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

ArriVent BioPharma

Bicara Therapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

Cogent Biosciences

Cargo Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Gyre Therapeutics

Immatics

Kura Oncology

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Novavax

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Relay Therapeutics

ARS Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vir Biotechnology

Xencor

Zymeworks

JP Morgan

Piper Sandler

WIIM

Upstream shares are trading higher after multiple firms initiated coverage on the stock with an Overweight rating.

Comments

Upstream Bio

Upstream Bio (UPB) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル